SI2952177T1 - Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p) - Google Patents
Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p)Info
- Publication number
- SI2952177T1 SI2952177T1 SI200832164T SI200832164T SI2952177T1 SI 2952177 T1 SI2952177 T1 SI 2952177T1 SI 200832164 T SI200832164 T SI 200832164T SI 200832164 T SI200832164 T SI 200832164T SI 2952177 T1 SI2952177 T1 SI 2952177T1
- Authority
- SI
- Slovenia
- Prior art keywords
- sphingosine
- phosphate
- compositions
- receptor modulators
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97948207P | 2007-10-12 | 2007-10-12 | |
EP15173766.5A EP2952177B1 (en) | 2007-10-12 | 2008-10-09 | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2952177T1 true SI2952177T1 (sl) | 2021-07-30 |
Family
ID=40032615
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200832164T SI2952177T1 (sl) | 2007-10-12 | 2008-10-09 | Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p) |
SI200831476T SI2465492T1 (sl) | 2007-10-12 | 2008-10-09 | Sestavi, ki obsegajo modulatorje receptorja sfingosin 1 fosfat (S1P) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200831476T SI2465492T1 (sl) | 2007-10-12 | 2008-10-09 | Sestavi, ki obsegajo modulatorje receptorja sfingosin 1 fosfat (S1P) |
Country Status (33)
Country | Link |
---|---|
US (6) | US8673918B2 (sl) |
EP (7) | EP3733161A1 (sl) |
JP (2) | JP6034000B2 (sl) |
KR (3) | KR20170021904A (sl) |
CN (1) | CN101820916A (sl) |
AR (1) | AR068986A1 (sl) |
AU (1) | AU2008310846C1 (sl) |
BR (1) | BRPI0818161B8 (sl) |
CA (2) | CA2925175A1 (sl) |
CL (1) | CL2008003003A1 (sl) |
CO (1) | CO6270342A2 (sl) |
DK (1) | DK2952177T3 (sl) |
EC (1) | ECSP10010169A (sl) |
ES (2) | ES2545361T3 (sl) |
HK (1) | HK1213768A1 (sl) |
HR (1) | HRP20150838T1 (sl) |
HU (2) | HUE027696T2 (sl) |
IL (3) | IL204514B (sl) |
JO (2) | JOP20080436B1 (sl) |
MA (1) | MA31799B1 (sl) |
MX (1) | MX337152B (sl) |
MY (1) | MY159358A (sl) |
NZ (1) | NZ600355A (sl) |
PE (2) | PE20090799A1 (sl) |
PL (2) | PL2952177T3 (sl) |
PT (2) | PT2952177T (sl) |
RU (1) | RU2010118457A (sl) |
SG (2) | SG187458A1 (sl) |
SI (2) | SI2952177T1 (sl) |
TN (1) | TN2010000136A1 (sl) |
TW (1) | TW200927142A (sl) |
WO (1) | WO2009048993A2 (sl) |
ZA (1) | ZA201001819B (sl) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8785484B2 (en) | 2008-03-17 | 2014-07-22 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective S1P1 receptor agonist |
US20110144082A1 (en) | 2008-08-18 | 2011-06-16 | David Leppert | Compounds for the treatment of peripheral neuropathies |
AR074826A1 (es) * | 2008-12-22 | 2011-02-16 | Novartis Ag | Regimen de dosificacion para un agonista de los receptores de s1p |
CN102264363A (zh) | 2008-12-22 | 2011-11-30 | 诺瓦提斯公司 | S1p受体激动剂的给药方案 |
US20130102682A1 (en) * | 2010-04-22 | 2013-04-25 | Ratiopharm Gmbh | Fingolimod in the form of a solid solution |
EA201291097A1 (ru) * | 2010-04-22 | 2013-04-30 | Рациофарм Гмбх | Финголимод в форме гранулированного расплава |
CN101973898B (zh) * | 2010-09-09 | 2013-06-19 | 南京明生医药技术有限公司 | 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用 |
PL2661261T3 (pl) * | 2011-01-07 | 2020-01-31 | Novartis Ag | Formulacje immunosupresyjne |
WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
ES2388273B1 (es) * | 2011-03-16 | 2013-10-01 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada |
AR085749A1 (es) * | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
WO2013019872A1 (en) | 2011-08-01 | 2013-02-07 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutical compositions comprising fingolimod |
RU2014120411A (ru) * | 2011-10-21 | 2015-11-27 | Новартис Аг | Схема приема модулятора или агониста рецептора s1p |
WO2013091704A1 (en) | 2011-12-22 | 2013-06-27 | Synthon Bv | Pharmaceutical composition comprising fingolimod |
RU2482842C1 (ru) * | 2012-04-26 | 2013-05-27 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения |
RU2506949C1 (ru) * | 2012-06-13 | 2014-02-20 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
RU2496486C1 (ru) * | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
JP2014129238A (ja) * | 2012-12-28 | 2014-07-10 | Lion Corp | エトドラク含有固形製剤 |
WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
EP2996681B1 (en) * | 2013-05-13 | 2019-12-18 | Synthon B.V. | Pharmaceutical composition comprising fingolimod |
MX2016001422A (es) * | 2013-07-29 | 2016-10-05 | Aizant Drug Res Solutions Pvt Ltd | Composicion farmaceutica de fingolimod. |
US20150141520A1 (en) * | 2013-11-18 | 2015-05-21 | Chandrasekhar Kandi | Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof |
EP3626713B1 (en) | 2014-02-13 | 2021-09-29 | Incyte Corporation | Cyclopropylamines for use as lsd1 inhibitors |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
CN106488915B (zh) | 2014-02-13 | 2020-10-02 | 因赛特公司 | 作为lsd1抑制剂的环丙胺 |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
SI3129006T1 (sl) * | 2014-04-10 | 2021-08-31 | Novartis Ag | Formulacija imunosupresivov |
US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US20170231928A1 (en) * | 2014-08-22 | 2017-08-17 | Sunshine Lake Pharma Co., Ltd. | Solid composition of fingolimod and preparation thereof |
WO2016042493A1 (en) | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
EP3247362A4 (en) * | 2014-11-17 | 2018-10-10 | Context Biopharma Inc. | Onapristone extended-release compositions and methods |
CA2974375A1 (en) * | 2015-01-20 | 2016-07-28 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
AU2016243939B2 (en) | 2015-04-03 | 2020-09-03 | Incyte Holdings Corporation | Heterocyclic compounds as LSD1 inhibitors |
MX2017013896A (es) * | 2015-04-28 | 2018-03-15 | Astellas Pharma Inc | Composicion farmaceutica para administracion oral. |
EA035534B1 (ru) | 2015-08-12 | 2020-06-30 | Инсайт Корпорейшн | Соли ингибитора lsd1 |
RU2639424C2 (ru) * | 2015-09-15 | 2017-12-21 | Закрытое Акционерное Общество "Биокад" | Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза |
US20180280322A1 (en) * | 2015-10-02 | 2018-10-04 | Mylan Inc. | Stable formulations of fingolimod |
SG11201809299QA (en) * | 2016-04-22 | 2018-11-29 | Incyte Corp | Formulations of an lsd1 inhibitor |
US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
EP3419607B1 (en) | 2017-03-29 | 2019-11-20 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
CA3105187A1 (en) | 2018-06-28 | 2020-01-02 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
CN117202893A (zh) * | 2021-04-14 | 2023-12-08 | 株式会社Lg化学 | 包含鞘氨醇-1-磷酸受体激动剂的可直接压缩的药物组合物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE172711T1 (de) * | 1992-10-21 | 1998-11-15 | Yoshitomi Pharmaceutical | 2-amino-1, 3- propandiolverbindung und immunosuppressium |
DE69524962D1 (de) | 1994-08-22 | 2002-02-14 | Welfide Corp | Benzolderivate und deren medizinische verwendung |
US5616621A (en) * | 1995-01-30 | 1997-04-01 | American Home Products Corporation | Taste masking liquids |
EP0812588B1 (en) | 1995-12-28 | 2004-10-13 | Mitsubishi Pharma Corporation | Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder |
AU735406B2 (en) | 1997-02-27 | 2001-07-05 | Novartis Ag | Pharmaceutical composition |
SI1002792T1 (sl) | 1997-04-04 | 2004-12-31 | Mitsubishi Pharma Corporation | 2-aminopropan-1,3-diolne spojine, njihova medicinska uporaba in intermediati pri njihovi sintezi |
JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
WO2002006268A1 (fr) | 2000-07-13 | 2002-01-24 | Sankyo Company, Limited | Derives d'alcool amino |
AU2001285331B2 (en) | 2000-08-31 | 2006-04-06 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
WO2003029184A1 (fr) | 2001-09-27 | 2003-04-10 | Kyorin Pharmaceutical Co., Ltd. | Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur |
JP4217620B2 (ja) | 2001-09-27 | 2009-02-04 | 杏林製薬株式会社 | ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤 |
EP1470137B1 (en) | 2002-01-18 | 2009-09-02 | Merck & Co., Inc. | Edg receptor agonists |
WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
KR101003877B1 (ko) | 2002-09-19 | 2010-12-30 | 교린 세이야꾸 가부시키 가이샤 | 아미노알코올 유도체와 그 부가염 및 면역 억제제 |
CN100344638C (zh) | 2003-02-18 | 2007-10-24 | 杏林制药株式会社 | 氨基膦酸衍生物、其加成盐以及s1p受体调节剂 |
MXPA05010860A (es) * | 2003-04-08 | 2006-05-25 | Novartis Ag | Composiciones solidas farmaceuticas que comprenden un agonista de receptor sip y y un alcohol de azucar. |
TW200503783A (en) | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
FR2854549B1 (fr) | 2003-05-06 | 2005-06-24 | Actis Ets | Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage |
PE20050158A1 (es) | 2003-05-19 | 2005-05-12 | Irm Llc | Compuestos inmunosupresores y composiciones |
MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
CN100431534C (zh) | 2003-06-24 | 2008-11-12 | 康涅狄格大学 | 血管内皮鞘氨醇-1-磷酸受体拮抗剂在制备药物中的应用 |
PL1660449T3 (pl) | 2003-08-28 | 2010-05-31 | Novartis Ag | Pochodne aminopropanolu |
CA2539033C (en) | 2003-09-12 | 2013-03-05 | Neuronova Ab | Treatment of disease or injury of the nervous system with fty720 |
UA74941C2 (en) | 2004-04-26 | 2006-02-15 | Fos Internat S A | A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same |
WO2005113330A1 (en) | 2004-05-05 | 2005-12-01 | Adler, Richard, S. | Systems and methods for protecting ship from attack on the surface or under water |
GB0504544D0 (en) | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
US8633161B2 (en) | 2005-03-24 | 2014-01-21 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of leukemia |
CN1891212B (zh) | 2005-07-07 | 2010-10-13 | 马启明 | 一种口服制剂及其制备方法 |
GT200600350A (es) * | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
KR101884047B1 (ko) * | 2006-09-26 | 2018-07-31 | 노파르티스 아게 | S1p 조정제를 포함하는 제약 조성물 |
-
2008
- 2008-10-09 PL PL15173766T patent/PL2952177T3/pl unknown
- 2008-10-09 RU RU2010118457/15A patent/RU2010118457A/ru unknown
- 2008-10-09 EP EP20176933.8A patent/EP3733161A1/en not_active Withdrawn
- 2008-10-09 EP EP16182588.0A patent/EP3120833A1/en not_active Withdrawn
- 2008-10-09 CA CA2925175A patent/CA2925175A1/en not_active Abandoned
- 2008-10-09 US US12/682,343 patent/US8673918B2/en not_active Expired - Fee Related
- 2008-10-09 EP EP20176935.3A patent/EP3733162A1/en active Pending
- 2008-10-09 BR BRPI0818161A patent/BRPI0818161B8/pt active IP Right Grant
- 2008-10-09 MY MYPI2010001202A patent/MY159358A/en unknown
- 2008-10-09 PT PT151737665T patent/PT2952177T/pt unknown
- 2008-10-09 EP EP08838495A patent/EP2209493A2/en not_active Withdrawn
- 2008-10-09 CN CN200880111160A patent/CN101820916A/zh active Pending
- 2008-10-09 AR ARP080104420A patent/AR068986A1/es not_active Application Discontinuation
- 2008-10-09 SI SI200832164T patent/SI2952177T1/sl unknown
- 2008-10-09 NZ NZ600355A patent/NZ600355A/xx not_active IP Right Cessation
- 2008-10-09 KR KR1020177004540A patent/KR20170021904A/ko not_active Application Discontinuation
- 2008-10-09 EP EP15173766.5A patent/EP2952177B1/en active Active
- 2008-10-09 SI SI200831476T patent/SI2465492T1/sl unknown
- 2008-10-09 AU AU2008310846A patent/AU2008310846C1/en active Active
- 2008-10-09 ES ES12155251.7T patent/ES2545361T3/es active Active
- 2008-10-09 HU HUE12155251A patent/HUE027696T2/en unknown
- 2008-10-09 JP JP2010529013A patent/JP6034000B2/ja active Active
- 2008-10-09 JO JOP/2008/0436A patent/JOP20080436B1/ar active
- 2008-10-09 KR KR1020167004264A patent/KR101710845B1/ko active IP Right Grant
- 2008-10-09 HU HUE15173766A patent/HUE053835T2/hu unknown
- 2008-10-09 PL PL12155251T patent/PL2465492T3/pl unknown
- 2008-10-09 WO PCT/US2008/079264 patent/WO2009048993A2/en active Application Filing
- 2008-10-09 DK DK15173766.5T patent/DK2952177T3/da active
- 2008-10-09 EP EP12155251.7A patent/EP2465492B1/en not_active Revoked
- 2008-10-09 MX MX2010003925A patent/MX337152B/es active IP Right Grant
- 2008-10-09 TW TW097139107A patent/TW200927142A/zh unknown
- 2008-10-09 SG SG2013002415A patent/SG187458A1/en unknown
- 2008-10-09 SG SG10201800085XA patent/SG10201800085XA/en unknown
- 2008-10-09 PT PT121552517T patent/PT2465492E/pt unknown
- 2008-10-09 EP EP13177175.0A patent/EP2653154A1/en not_active Withdrawn
- 2008-10-09 KR KR1020107010336A patent/KR101600098B1/ko active Application Filing
- 2008-10-09 ES ES15173766T patent/ES2864671T3/es active Active
- 2008-10-09 CA CA2699788A patent/CA2699788C/en active Active
- 2008-10-10 PE PE2008001756A patent/PE20090799A1/es not_active Application Discontinuation
- 2008-10-10 CL CL2008003003A patent/CL2008003003A1/es unknown
- 2008-10-10 PE PE2012002520A patent/PE20130309A1/es not_active Application Discontinuation
-
2010
- 2010-03-15 IL IL204514A patent/IL204514B/en active IP Right Grant
- 2010-03-15 ZA ZA2010/01819A patent/ZA201001819B/en unknown
- 2010-03-26 TN TNP2010000136A patent/TN2010000136A1/fr unknown
- 2010-04-28 CO CO10050315A patent/CO6270342A2/es not_active Application Discontinuation
- 2010-04-30 MA MA32805A patent/MA31799B1/fr unknown
- 2010-05-11 EC EC2010010169A patent/ECSP10010169A/es unknown
- 2010-10-18 HK HK16101686.9A patent/HK1213768A1/zh unknown
-
2014
- 2014-01-27 US US14/164,623 patent/US20140142192A1/en not_active Abandoned
- 2014-12-04 JP JP2014246066A patent/JP2015091822A/ja active Pending
-
2015
- 2015-02-25 US US14/631,102 patent/US9399066B2/en active Active
- 2015-08-06 HR HRP20150838TT patent/HRP20150838T1/hr unknown
-
2016
- 2016-06-15 US US15/183,523 patent/US20160296481A1/en not_active Abandoned
-
2017
- 2017-02-14 US US15/432,628 patent/US20170151195A1/en not_active Abandoned
- 2017-09-08 US US15/698,742 patent/US20170368001A1/en not_active Abandoned
- 2017-11-19 IL IL255737A patent/IL255737B/en active IP Right Grant
-
2020
- 2020-10-13 IL IL277999A patent/IL277999A/en unknown
-
2021
- 2021-07-08 JO JOP/2021/0187A patent/JOP20210187A1/ar unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277999A (en) | Compounds containing modulators of the sphingosine 1 phosphate (S1P) receptor | |
HUS2000038I1 (hu) | Szfingozin foszfát receptor új modulátorai | |
HK1214758A1 (zh) | 用於治療多發硬化症的 受體調節劑 | |
LT3103448T (lt) | Farmacinės kompozicijos, apimančios s1p moduliatorių | |
HK1213873A1 (zh) | 選擇性的雜環 -磷酸鞘氨醇受體調節劑 | |
HK1157146A1 (en) | Composition for regulating lipid metabolism | |
IL209306A (en) | Compounds 1, 2, 4 - Oxadiazole as modulators of sphingosine phosphate receptors | |
EP2178539A4 (en) | PHOSPHOLIPIDE COMPREHENSIVE COMPOSITIONS | |
GB0722340D0 (en) | Sphingosine-1-phosphate (S1P) receptor compounds | |
GB0610311D0 (en) | Bisphosphonate formulation |